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This best evidence topic was investigated according to a described protocol. The question asked was:
should patients on acetylsalicylic acid (ASA) for secondary prevention stop or continue the medication
prior to elective, abdominal surgery. Using the reported search 826 papers were found of which ﬁve
represented the best evidence to answer the clinical question. The strongest evidence was from a ran-
domized controlled trial (RCT) speciﬁcally looking at elective abdominal surgery, which showed no
statistically signiﬁcant difference between ASA continuation and discontinuation in terms of haemor-
rhagic or thrombotic events. Two other RCT’s examined elective non-cardiac surgery but only a minor
proportion (20.6% and 23.6%) of patients underwent abdominal surgery and data were unavailable
regarding adverse events in these patients. However, one of these trials did show a 7.2% absolute risk
reduction in postoperative cardiac adverse events when ASA was continued. One prospective cohort
study found no difference between ASA maintenance and cessation except for longer duration of surgery
in the ASA continuation group. Finally one recent retrospective cohort study revealed similar bleeding
rates between ASA-treated and non-ASA-treated patients but increased cardiac complication rates in the
ASA group.
Only two studies compared continuation versus discontinuation of ASA, while the remaining three
looked at patients on ASA versus those not on ASA. This heterogeneity in methodology makes it difﬁcult
to draw justiﬁable conclusions from the data. However, it appears that continuing ASA isn’t associated
with excessive bleeding. Further adequately powered trials with well-deﬁned end points are needed to
answer this important clinical question.
 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
This best evidence topic was generated according to the struc-
ture outlined in the International Journal of Surgery.1
2. Clinical scenario
At a regional cancer multidisciplinary team meeting, a diabetic
patient with potentially curable colorectal cancer is being listed for
an elective anterior resection. He has had a previous transient
ischaemic attack (TIA) and is on acetylsalicylic acid (ASA) for sec-
ondary prevention. The treating surgeon wants his aspirin dis-
continued preoperatively while his colleague argues that thisSurgery, University Hospital
61 234920; fax: þ353 61
ciates Ltd. Published by Elsevier Ltapproach is unproven. You decide to assess the literature to resolve
this question.
3. Three-part question
In [patients on ASA for secondary prevention] who are [under-
going elective abdominal surgery], should ASA be [continued or
discontinued perioperatively].
4. Search strategy
We screened the Medline database and the Cochrane Central
Register of Controlled Trials (up to August 2013) using the terms
([aspirin AND perioperative] OR [aspirin AND abdominal surgery]).
The search was limited to English language and cross-referencing
from papers recovered in the original search identiﬁed additional
articles. Studies that provided results speciﬁcally related to aspirin
were included; studies that provided results for antiplateletd. All rights reserved.
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sults were excluded (Fig. 1). Studies on orthopaedic surgery, cardiac
surgery, vascular surgery, neurosurgery, ophthalmic surgery, ear,
nose and throat surgery, urology and emergency surgery were also
excluded.
5. Search outcome
The above search yielded 744 Medline citations and 82 trials
from the Cochrane Central Register of Controlled Trials. Five studies
provided the best evidence to answer the question.
6. Results
3 randomized controlled trials,1 retrospective and 1 prospective
observational study were included in the BET article. These are
tabulated in Table 1.
7. Discussion
Antolovic D et al.2 randomized 52 low or intermediate risk pa-
tients to either ASA continuation (n ¼ 26) or discontinuation
(n ¼ 26) prior to undergoing elective cholecystectomy, inguinal
hernia repair or colorectal surgery. Patients in the ASA continuation
group continued the medication throughout the entire periopera-
tive period while those in the ASA cessation group stopped ASA 5
days prior to surgery and recommenced it on the 5th postoperative
day. Primary study end-points included incidence of haemorrhagic
as well as thromboembolic (TE) complications within 30 days after
surgery. Secondary end-points comprised duration of surgical
intervention, intraoperative blood loss, transfusion requirements,Fig. 1. Diagram summarizinglength of post-operative hospital stay (LOS), medical and surgical
morbidity and need for readmission. One of 26 (3.8%) patients in
the ASA maintenance group suffered a postoperative haemorrhage,
requiring re-intervention, versus none in the ASA cessation group
(p ¼ 0.31). This was attributed to arterial bleeding resulting from
the surgical intervention. There were no TE events or mortality in
either group. Both groups were similar in terms of median intra-
operative blood loss (40 mls in ASA continuation vs. 50 mls in ASA
discontinuation groups, p ¼ 0.41), transfusion requirements (3
patients in ASA continuation vs. 2 patients in ASA discontinuation
groups, p ¼ 0.58), median duration of surgery (85 [range 53e240]
minutes in ASA maintenance vs. 106 [range 26e330] minutes in
ASA cessation, p ¼ 0.40) and median LOS (3 days in both, p ¼ 0.82).
Furthermore, the authors reported no signiﬁcant difference when
comparing laparoscopic versus open surgical procedures. The
principle limitation of the study by Antolovic et al. is the small
sample sizee it was a pilot study that aimed to assess the feasibility
of a larger adequately powered study. Furthermore, external val-
idity is limited by the exclusion of patients who were deemed high
risk by the cardiology team.
Mantz J et al.3 performed a randomized, blinded, multicenter,
placebo-controlled trial comparing the effect of continuation
versus cessation of low-dose ASA (75 mg) on thrombotic and
bleeding events in 291 high-risk patients undergoing intermediate-
or high-risk non-cardiac surgery (including orthopaedic, abdom-
inal, urologic, oncologic ENT and vascular surgery but excluding
carotid endarterectomy and coronary artery bypass grafting). They
replaced non-aspirin anti-platelet agents with aspirin (n ¼ 145) or
placebo (n¼ 146) beginning 10 days before, and continued until the
morning of surgery. After surgery, aspirin was resumed in both
groups only when the surgeon deemed the bleeding riskthe results of the search.
Table 1
Best evidence papers included in study.
Author, date and
country of research
Patient group Study type and level of
evidence
Outcomes Key results Comments
Antolovic D et al.2
2012
Langenbecks Arch Surg
Germany
52 non-high risk patients on
low-dose acetylsalicylic acid
(ASA) undergoing elective
cholecystectomy (n ¼ 13),
inguinal hernia repair (n ¼ 23)
or colorectal surgery (n ¼ 16)
ASA indication:
CAD (30 patients)
PCI ± stent (14 patients)
Non-coronary stent or
vascular prosthesis (6
patients)
CABG (6 patients)
Dilated cardiomyopathy (3
patients)
CCF (9 patients)
Stable/unstable angina
pectoris (10 patients)
CVD (19 patients)
Cardiac arrhythmias (12
patients)
Valvular heart disease (13
patients)
Cardiac transplant (2 patients)
PVD (5 patients)
Type 2 DM (10 patients)
DVT (1 patient)
Other (including smoking,
hyperlipidaemia, extremity
vessel aneurysms; 35 patients)
ASA continuation group: 26
patients
(19 patients had open while 7
had laparoscopic procedures)
ASA discontinuation group: 26
patients
(16 patients had open, 9 had
laparoscopic and 1 had a lap-
> open procedures)
Randomized controlled trial
Level II
Primary end-points: Incidence of
major haemorrhagic and
thromboembolic (TE) events within
the ﬁrst 30 postoperative days
Secondary end-points:
Duration of surgical intervention,
intraoperative blood loss,
transfusion requirements, length of
post-operative hospital stay,
medical and surgical morbidity and
need for readmission
1 patient (3.8%) in ASAmaintenance
group who had right
hemicolectomy had a postoperative
bleed, requiring reoperation vs.
none in ASA discontinuation group
(p ¼ 0.31)
No TE events or mortality in either
group
No statistically signiﬁcant
differences in secondary end-points
between groups
Bleeding in ASA continuation group
attributed to arterial bleeding,
secondary to surgical intervention
Small sample size but no
statistically signiﬁcant differences
between maintenance and
cessation of low-dose ASA in low-
and intermediate-risk patients
undergoing elective abdominal
surgery in terms of occurrence of
bleeding and thrombotic
complications
Mantz J et al.3
2011
Br J Anaes
France
291 at-risk patients undergoing
elective non-cardiac high- or
intermediate-risk surgery, on
low-dose ASA (n ¼ 145) or
placebo (n ¼ 146)
ASA indication:
Cigarette smoking (167
patients)
Hypertension (191 patients)
Hypercholesterolaemia (183
patients)
Randomized, blinded, placebo-
controlled, multicenter trial
Level II
Primary end-point: Weighted (as
per Delphi consensus) composite
score including death, major
thrombotic events (stroke, TIA, ACS,
PAI, MAI, venous thrombosis and
PE) and major bleeding events
(cerebral haemorrhage, intra- or
retroperitoneal haemorrhage,
bleeding requiring an intervention
or requiring 3 units of RBC)
recorded between inclusion and
day 30 after surgery
A total of 35 major adverse events
occurred in 31 patients (18 in
aspirin group vs. 17 in placebo
group) by day 30 postoperatively:
- Deaths: 2 each in aspirin and
placebo group (p ¼ 1.0)
- Thrombotic events: 6 in aspirin
vs. 5 in placebo groups (p ¼ 0.8)
- Bleeding events: 10 each in
aspirin and placebo group
(p ¼ 1.0)
Study initially powered to recruit
1421 patients but stopped after 291
because of major recruitment
difﬁculties
Number of patients who had
abdominal surgery and suffered
major adverse events is unknown
as data not provided by authors
Protocol used by authors was low-
dose ASA/placebo started 10 days
before surgery and continued until
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Diabetesmellitus (70 patients)
ACS (120 patients)
Obesity (69 patients)
Cardiac failure (16 patients)
Stroke (38 patients)
VTE (21 patients)
CEA (18 patients)
Lower limb arteriopathy (73
patients)
History of ischaemia (38
patients)
60 patients in total (25 in
aspirin group and 35 in placebo
group) underwent abdominal
surgery
Carotid endarderectomy,
coronary bypass grafting and
intracranial neurosurgery were
excluded
Secondary end-points:
Weighted composite end-point on
postoperative days 7 and 180, and
each element separately No signiﬁcant difference observed
in primary outcome score between
either group [mean (SD) ¼ 0.67
(2.05) in aspirin group vs. 0.65
(2.04) in placebo group, p ¼ 0.94]
morning of surgery, and normal
anti-platelet agents resumed after
surgery when postoperative
bleeding risk was considered
acceptable. However, exact number
of days when patients were on no
anti-platelet agents postoperatively
is unknown. Moreover, 5 of 11
major thrombotic events occurred
between day 1 and 3
postoperatively
Oscarsson A et al.4
2010
Br J Anaes
Sweden
220 high-risk patients
(excluding those with
intracoronary stents)
undergoing elective non-
cardiac high- (oesophageal,
liver or pancreatic surgery) or
intermediate-risk (head and
neck, intrathoracic, advanced
bowel, gastric, open/
transurethral prostate,
cystectomy, hip/knee
arthroplasty, nephrectomy,
intra-abdominal or pelvic
cancer) surgery, on low-dose
ASA (n ¼ 109) or placebo
(n ¼ 111)
ASA indication:
Ischaemic heart disease
(including CABG and PCI; 220
patients)
CCF (31 patients)
Renal impairment (8 patients)
CVD (49 patients)
IDDM (50 patients)
Patients undergoing vascular
surgery were excluded
52 patients in total (24 in
aspirin group and 28 in placebo
group) underwent abdominal
surgery
Randomized double-blind
placebo-controlled
multicenter trial
Level II
Primary end-point:
Incidence of postoperative
myocardial damage (TnT > 0.04)
Secondary end-points:
MACEs (including myocardial
infarction, cardiac arrest, severe
arrhythmia or cardiovascular
death), cardio-cerebrovascular
complications (including MACE or
stroke/TIA) and perioperative blood
loss and major bleeding (including
postoperative bleeding requiring
reoperation, gastrointestinal
bleeding, intracranial haemorrhage,
or spinal/epidural haematoma)
within the ﬁrst 30 post-operative
days
Packed red blood cell, plasma and
platelet transfusion
4 patients (3.7%) in aspirin vs. 10
patients (9.0%) in placebo group had
postoperative myocardial damage
(p ¼ 0.10)
2 patients (1.8%) in aspirin vs. 10
patients (9.0%) in placebo group had
a MACE within the ﬁrst 30
postoperative days (p ¼ 0.02)
3 patients (2.7%) in aspirin vs. 10
patients (9.0%) in placebo group had
a cardio-cerebrovascular event
within the ﬁrst 30 postoperative
days (p ¼ 0.049)
No signiﬁcant differences between
groups in terms of bleeding
complications
Study initially powered to recruit
540 patients but stopped
prematurely as new
recommendations on management
of high risk patients on ASA
undergoing surgery were published
during patient recruitment
Number of patients who had
abdominal surgery and suffered
postoperative myocardial damage
and/or MACEs is unknown as data
not provided by authors
Older deﬁnitions of high- and
intermediate-risk surgery from
2002 used in this study, as opposed
to newer 2010 guidelines issued by
European Societies of Cardiology
and Anaesthesiology
Even though no statistically
signiﬁcant differences between
haemorrhagic complications was
observed in either group, study was
underpowered to evaluate these
10 patients in total discontinued
intervention for failing to comply
with treatment regimen but were
still included in ﬁnal statistical
analysis
(continued on next page)
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Table 1 (continued )
Author, date and
country of research
Patient group Study type and level of
evidence
Outcomes Key results Comments
However, ASA treatment resulted in
a 7.2% absolute risk reduction and
80.0% relative risk reduction in
postoperative MACE, with a
number needed to treat of 14
patients
Ono K et al.5
2013
Surg Laparosc Endosc
Percutan
Tech
Japan
488 patients undergoing
elective laparoscopic
cholecystectomy (n ¼ 270) and
laparoscopic colorectal cancer
resections (n ¼ 218)
ASA indication:
CAD (30 patients)
Cerebral infarction (16
patients)
PVD (5 patients)
AF (3 patients)
TIA (2 patients)
In total, 52 patients undergoing
surgery were receiving 81 mg
or 100 mg ASA (29 underwent
laparoscopic cholecystectomy
and 23, laparoscopic colorectal
cancer resections)
Prospective, observational
study Level III evidence
Primary end-point:
Blood loss and postoperative
morbidity
No signiﬁcant differences in
investigated outcomes between
aspirin vs. non-aspirin groups in
cholecystectomy patients except
for longer duration of surgical
procedure in aspirin group
(p ¼ 0.008)
No signiﬁcant differences in
outcomes between aspirin vs. non-
aspirin groups in colorectal cancer
resected patients
Non-randomized, small sample size
study
Postoperative morbidity as a
primary end-point was not well
deﬁned
Wolf AM et al.6
2013
Surgery
United States
1017 patients undergoing
elective pancreatic resections
ASA indication:
Not documented
ASA group (81 or 325 mg daily):
289 patients
Non-ASA group: 728 patients
Retrospective, observational
study Level III evidence
Primary outcomes: intraoperative
blood loss, intra- or postoperative
RBC transfusion, major
cardiovascular events and 30-day
all cause mortality
Secondary outcomes: anastomotic
leak rate, length of postoperative
hospital stay and readmissions
No difference in bleeding rates
between groups but increased rate
of cardiac adverse events in ASA
group (10.1% vs. 7%, p ¼ 0.107)
No difference in secondary
outcomes studied
Non-randomized, retrospective
observational study
19% of patients were on 325 mg,
versus 81% on 81 mg of ASA
Paradoxical ﬁnding of increased
(although not signiﬁcant) cardiac
rates in ASA group
ACS, Acute Coronary Syndrome; AF, Atrial Fibrillation; CAD, Coronary Artery Disease; CABG. Coronary Artery Bypass Grafting; CCF, Congestive Cardiac Failure; CEA, Carotid Endarderectomy; CVD, Cerebrovascular Disease; DVT,
Deep Venous Thrombosis; IDDM, Insulin Dependent Diabetes Mellitus; MAI, Mesenteric Arterial Ischaemia; MACE, Major Adverse Cardiac Event; PCI, Percutaneous Coronary Intervention; PVD, Peripheral Vascular Disease; PAI,
Peripheral Arterial Ischaemia; PE, Pulmonary Embolism; RBC, Red Blood Cell; TIA, Transient Ischaemic Attack; TnT, cardiac Troponin T; VTE, Venous Thromboembolism.
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BEST EVIDENCE TOPICacceptable. In total, 60 patients (25 in aspirin group and 35 in
placebo group) underwent abdominal surgery. The primary end-
point was a weighted (according to a Delphi consensus) compos-
ite score evaluating both bleeding and thrombotic events occurring
within the 30 days following surgery. There was no signiﬁcant
difference in the mean outcome scores between either group
[mean (SD) ¼ 0.67 (2.05) in aspirin group vs. 0.65 (2.04) in placebo
group, p ¼ 0.94]. The principle limitation is that the study was
underpowered. Furthermore, 45% (5/11) of thrombotic complica-
tions occurred between postoperative day 1 and 3, a window
during which patients may have been on no anti-platelet agents
whatsoever, as the treatment regimen continued only until the
morning of surgery e the patients’ usual anti-platelets were only
resumed when the authors deemed the risk of postoperative
bleeding acceptable. Finally, the number of adverse events specif-
ically relating to abdominal surgery is not known as these data
were not provided.
In the randomized, double-blind, placebo-controlledmulticenter
trial byOscarssonet al.,4 theyassessed220high-risk (excluding those
with coronary stents) patients undergoingelectivenon-cardiachigh-
(oesophageal, liver or pancreatic surgery) or intermediate-risk (head
and neck, intrathoracic, advanced bowel, gastric, open/transurethral
prostate, cystectomy, hip/knee arthroplasty, nephrectomy, intra-
abdominal or pelvic cancer) surgery. Patients were randomized to
either daily low-dose (75 mg) ASA (n ¼ 109) or placebo (n ¼ 111) 7
days before surgery until the third postoperative day. In total, 52
patients (24 in aspirin, and 28 in placebo group) underwent elective
abdominal surgery. Primary end-point was the incidence of post-
operative myocardial damage (troponin T > 0.04 ng/ml), while sec-
ondary end-points comprisedmajor adverse cardiac events (MACEs)
[includingmyocardial infarction, cardiac arrest, severe arrhythmia or
cardiovascular death], cardio-cerebrovascular complications
(including MACE or stroke/TIA), perioperative blood loss and major
bleeding complications (including postoperative bleeding requiring
reoperation, gastrointestinal bleeding, intracranial haemorrhage, or
spinal/epidural haematoma) within the ﬁrst 30 post-operative days,
as well as packed red blood cell, plasma and platelet transfusion re-
quirements. There were no statistically signiﬁcant differences be-
tween the two groups in terms of postoperative myocardial damage
or bleeding complications. However, 1.8% of aspirin-treated patients
versus 9.0% of placebo-treated patients, and 2.7% of aspirin-treated
patients versus 9.0% of placebo-treated patients had a MACE
(p ¼ 0.02) and a cardio-cerebrovascular complication (p ¼ 0.049)
respectively, within the ﬁrst month following surgery. Treatment
with ASA was associated with a 7.2% absolute risk reduction, and
80.0% relative risk reduction inpostoperativeMACE,withnumbers to
treat of 14 patients. Unfortunately, datawere unavailable on the true
number of patients with myocardial damage/MACEs who had un-
dergone abdominal surgery only.
In the Japanese prospective, observational cohort study of Ono
et al.,5 52 ASA-treated (81 or 100 mg ASA) patients were compared
with 436 patients not on aspirin, in regards to blood loss and
postoperative morbidity. All patients underwent either elective
laparoscopic cholecystectomy (n ¼ 270) or laparoscopic colorectal
cancer resection (n ¼ 218) and patients on ASA were instructed to
continue the medication until the day of surgery. After surgery, ASA
was restarted as soon as oral intake was established. They found no
signiﬁcant difference in outcomes between either group except for
longer duration of laparoscopic cholecystectomy in aspirin-treated
patients. However, the study was underpowered in that the small
percentage of patients taking ASA (10.6%) was not enough to detect
ASA-induced change in blood loss or perioperative morbidity.
Additionally, the thrombotic risk of aspirinwithdrawal could not be
determined as appraisals were only made between patients on ASA
and those who were not on ASA before surgery.Wolf AM et al.6 conducted a retrospective cohort study
comparing 289 patients on daily 81 (or 325) mg ASA with 728
patients not on ASA undergoing elective pancreatoduodenectomy,
distal pancreatectomy and total pancreatectomy. Patients in the
ASA group continued the medication until the morning of surgery
and restarted it on postoperative day 1. There were no differences
between the two groups in terms of bleeding complications, but
there were increased cardiac complications (especially myocardial
infarction) in the ASA group (10.1% vs. 7.0%, p ¼ 0.107). The authors
attributed this ﬁnding to the presence of increased cardiac risk in
the aspirin group.
8. Clinical bottom line
The evidence on this important clinical dilemma is weak and it
is difﬁcult to make recommendations based on the available data.
The study protocols/patient cohorts were heterogenous and
employed varying doses of ASA as well as small sample sizes. Only
two of the included studies assessed the effects of continuing
versus discontinuing ASA, where as the remaining three looked at
patients on ASA versus patients not on ASA (with the potential
effects of ASA withdrawal syndrome unjustiﬁably eliminated).
Therefore, the conclusions from these studies are not generalizable.
This is unfortunate but reinforces the notion that the evidence in
the literature is lacking on this important issue and begs for future
adequately powered trials with well-deﬁned end points. However,
the limited data from this review suggest that bleeding complica-
tions are unlikely to occur when ASA is maintained throughout
elective, abdominal surgery.
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